Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs


Making Markets for Merit Goods

This is a joint post with Josh Busby

Our research on the political economy of antiretrovirals (ARVs) is motivated by a key puzzle: why were AIDS activists and AIDS policy entrepreneurs successful in putting universal access to treatment on the international agenda when so many other global campaigns--whether in health care or other issue areas like climate change--have either failed or struggled to have much impact. In our paper, we make the case that the market for ARVs was politically constructed, meaning that activists had to bring the demand and supply sides of the market together through a variety of tactics and strategies (Tim Bartley makes a similar argument on forest certification schemes).

Will a New NIH-Funded Study Tell Us Whether Immediate AIDS Treatment Slows HIV Transmission?

Each year in Sub-Saharan Africa there are about 2-million new cases of HIV infection, most of whom would not need antiretroviral therapy (ART) under current guidelines for 8 to 12 more years. Since donors have not managed to place on treatment more than about half of those needing it each year, the 8 to 12 year lag between infection and need for treatment has been seen as a breathing space.